Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

235
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
235
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

200
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
200
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

888
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
888
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

257
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
257
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

223
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
223
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

685
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
685

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between locomotor muscle quality and cardiac function during exercise in heart failure with preserved ejection fraction.

European journal of heart failure·2024
Same author

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.

The New England journal of medicine·2024
Same author

Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.

Circulation·2024
Same author

Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial.

Nature medicine·2024
Same author

Prevalence of HFpEF in Isolated Severe Secondary Tricuspid Regurgitation.

JAMA cardiology·2024
Same author

The myocardial function index (MFI): An integrated measure of cardiac function in AL-cardiomyopathy.

International journal of cardiology. Heart & vasculature·2024

Related Experiment Video

Updated: Jan 9, 2026

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
07:41

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

4.2K

Refining Atrial Shunt Therapy for Heart Failure With Preserved Ejection Fraction: Lessons From Pivotal Randomized

Dylan J Gyberg1, Jan Komtebedde2, Uma Mylavarapu3

  • 1Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois; University of Minnesota Medical School, Minneapolis, Minnesota.

Journal of Cardiac Failure
|December 1, 2025
PubMed
Summary

Interatrial shunts may benefit select heart failure with preserved ejection fraction (HFpEF) patients. Careful patient selection, focusing on those without pulmonary vascular disease, is crucial for positive outcomes, as indicated by trial comparisons.

Keywords:
Invasive hemodynamicsexercise testingpulmonary vascular diseaserandomized clinical trialresponder analyses

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.9K
Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
09:23

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension

Published on: February 11, 2017

17.3K

Related Experiment Videos

Last Updated: Jan 9, 2026

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
07:41

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

4.2K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.9K
Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
09:23

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension

Published on: February 11, 2017

17.3K

Area of Science:

  • Cardiology
  • Medical Devices
  • Clinical Trials

Background:

  • Heart failure with preserved ejection fraction (HFpEF) presents a significant clinical challenge with limited therapeutic options.
  • Elevated left atrial pressure is a critical factor in HFpEF symptomology and progression, representing a key therapeutic target.
  • Interatrial shunts are being investigated as a novel approach to reduce left atrial pressure and improve HFpEF outcomes.

Purpose of the Study:

  • To compare the design and outcomes of the REDUCE LAP-HF II and RELIEVE-HF trials investigating interatrial shunts in HFpEF.
  • To explore potential concordance in the seemingly conflicting results of these two major trials.
  • To highlight the importance of detailed patient phenotyping for identifying responders to interatrial shunt therapy.

Main Methods:

  • Comparative analysis of two randomized controlled trials (REDUCE LAP-HF II and RELIEVE-HF) on interatrial shunts for HFpEF.
  • Examination of patient subgroups, focusing on characteristics such as ejection fraction, pulmonary vascular disease, and cardiac rhythm management devices.
  • Inclusion of invasive exercise hemodynamics and echocardiographic data in the phenotyping approach.

Main Results:

  • REDUCE LAP-HF II identified a responder subgroup (EF >40%, no latent pulmonary vascular disease or device) with significant clinical benefits.
  • Non-responders in REDUCE LAP-HF II and patients in RELIEVE-HF (EF >40%) showed worse outcomes, sharing characteristics like advanced echocardiographic abnormalities and elevated pulmonary vascular resistance.
  • The findings suggest that seemingly conflicting trial results may be reconciled through careful patient selection criteria.

Conclusions:

  • Interatrial shunts may offer clinical benefits for a carefully selected HFpEF population.
  • Detailed patient phenotyping, including invasive hemodynamics, is essential for optimizing interatrial shunt therapy efficacy.
  • Refined patient selection strategies are critical for ongoing and future trials, such as RESPONDER-HF, aiming to improve outcomes in HFpEF and HF with mildly reduced EF.